Arlene Siefker-Radtke, MD, is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, Houston, TX.
Future Directions in Urothelial Cancer Treatment: Clinical Trials and Novel Agents
September 21st 2023Arlene Siefker-Radtke, MD, highlights the ongoing quest for improved treatment options in metastatic urothelial cancer, emphasizing the role of clinical trials and novel agents in addressing unmet needs.
Second-Line Strategies in Metastatic Urothelial Cancer: Balancing Options and Risks
September 21st 2023Arlene Siefker-Radtke, MD, delves into the complexities of managing progressive disease in metastatic urothelial cancer, outlining considerations for immune checkpoint inhibitors, antibody drug conjugates, and other targeted therapies.
Frontline Options for Metastatic Urothelial Cancer: Tailoring Treatment Choices
September 21st 2023Diverse approaches to frontline treatment for metastatic urothelial cancer, including eligibility for cisplatin-based chemotherapy, alternative regimens, and the impact of drug shortages on treatment decisions.
Early Mutation Profiling in Urothelial Cancer: A Path to Targeted Therapy
September 21st 2023Arlene Siefker-Radtke, MD, emphasizes the importance of early mutation profiling in metastatic urothelial cancer and highlights the potential for targeted agents and clinical trials to improve treatment outcomes.
Biomarker Testing in Urothelial Cancer: Implications for Treatment Decisions
September 21st 2023The evolving role of biomarker testing, including PD-L1 expression and mutations like FGFR3, in guiding treatment decisions for urothelial cancer patients, shedding light on their clinical significance and potential impact on therapeutic choices.
Discussion on Trial Investigating Erdafitinib in Patients With Urothelial Cancer
June 8th 2018Arlene O. Siefker-Radtke, MD, professor of genitourinary medical oncology at MD Anderson Cancer Center, discusses the results presented at the 2018 ASCO Annual Meeting from a phase II cohort investigating erdafitinib in previously treated patients with urothelial cancer. Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor that targets FGFR 1 through 4 and has previously shown promising activity.